Sun Pharma gets CDSCO nod for Tofacitinib
In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis. This came after the drug maker Sun Pharma presented...
In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.
This came after the drug maker Sun Pharma presented the proposal for manufacturing and marketing of Tofacitinib ER Tablets 11mg along with bioavailability (BE) Study report before the committee.
For more information check out the full story on the link below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd